DaVita (NYSE:DVA) Shares Down 5.3% - Here's Why

Key Points

• DaVita shares fell 5.3% to about $183.49, with trading volume below the stock’s average daily level.
• Analyst sentiment remains moderately positive, with four Buy ratings and three Holds; the average price target is $233.43, despite Truist cutting its target to $215.
• The company recently beat quarterly estimates, reporting $4.02 in EPS and $3.55 billion in revenue, while revenue grew 5.2% year over year; institutional investors own 90.12% of the stock.

Shares of DaVita Inc. (NYSE:DVA - Get Free Report) dropped 5.3% during trading on Thursday . The stock traded as low as $184.18 and last traded at $183.4890. Approximately 621,564 shares were traded during trading, a decline of 32% from the average daily volume of 917,575 shares. The stock had previously closed at $193.86.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DVA. Truist Financial cut their price target on DaVita from $250.00 to $215.00 and set a "hold" rating for the company in a research note on Friday, August 7th. Oppenheimer set a $220.00 target price on shares of DaVita in a research note on Friday, August 7th. Zacks Research lowered shares of DaVita from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 6th. TD Cowen upgraded shares of DaVita from a "hold" rating to a "buy" rating and boosted their target price for the company from $201.00 to $220.00 in a research note on Friday, August 7th. Finally, UBS Group upped their price objective on DaVita from $235.00 to $270.00 and gave the company a "buy" rating in a research note on Friday, July 10th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, DaVita has an average rating of "Moderate Buy" and an average target price of $233.43.

DaVita Stock Down 5.4%

The firm's 50-day simple moving average is $201.51 and its 200-day simple moving average is $186.53. The firm has a market capitalization of $11.71 billion, a PE ratio of 14.99, a price-to-earnings-growth ratio of 0.49 and a beta of 0.83.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The business's revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities research analysts forecast that DaVita Inc. will post 14.57 earnings per share for the current year.

Hedge Funds Weigh In On DaVita

Large investors have recently modified their holdings of the stock. Root Financial Partners LLC boosted its stake in shares of DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company's stock worth $29,000 after buying an additional 105 shares during the last quarter. Sankala Group LLC purchased a new position in DaVita in the fourth quarter worth about $39,000. Fideuram Asset Management Ireland dac purchased a new stake in shares of DaVita during the 4th quarter valued at about $49,000. Western Wealth Management LLC bought a new position in DaVita in the first quarter worth approximately $60,000. Finally, Canada Post Corp Registered Pension Plan raised its holdings in DaVita by 51.6% in the 4th quarter. Canada Post Corp Registered Pension Plan now owns 558 shares of the company's stock worth $63,000 after purchasing an additional 190 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Company Profile

DaVita Inc NYSE: DVA is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.